Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Jounce Therapeutics Inc (JNCE)

Jounce Therapeutics Inc (JNCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 162,504
  • Shares Outstanding, K 34,068
  • Annual Sales, $ 147,870 K
  • Annual Income, $ 56,820 K
  • 60-Month Beta 2.16
  • Price/Sales 1.16
  • Price/Cash Flow 2.83
  • Price/Book 1.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.69
  • Number of Estimates 5
  • High Estimate -0.64
  • Low Estimate -0.79
  • Prior Year 2.90
  • Growth Rate Est. (year over year) -123.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.43 +5.87%
on 08/07/20
6.20 -24.35%
on 07/13/20
-1.21 (-20.51%)
since 07/10/20
3-Month
4.30 +9.07%
on 05/15/20
8.09 -42.03%
on 06/29/20
-0.25 (-5.06%)
since 05/12/20
52-Week
2.79 +68.10%
on 10/04/19
10.00 -53.10%
on 12/26/19
+0.40 (+9.32%)
since 08/12/19

Most Recent Stories

More News
Jounce Therapeutics Reports Second Quarter 2020 Financial Results

- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 -

JNCE : 4.70 (-1.47%)
Jounce Therapeutics to Participate in a Fireside Chat at BTIG Virtual Biotechnology Conference 2020

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray,...

JNCE : 4.70 (-1.47%)
Jounce Therapeutics to Announce Second Quarter 2020 Financial Results and Host Conference Call on Friday, August 7, 2020

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report...

JNCE : 4.70 (-1.47%)
Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting

- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells -

JNCE : 4.70 (-1.47%)
Jounce Therapeutics to Participate in a Virtual Fireside Chat at the Raymond James Human Health Innovation Conference

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management...

JNCE : 4.70 (-1.47%)
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has regained...

CELGZ : 0.47 (+2.15%)
JNCE : 4.70 (-1.47%)
Jounce Therapeutics to Hold Virtual Meeting of Stockholders

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will now host...

JNCE : 4.70 (-1.47%)
Jounce Therapeutics to Present First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at the American Association for Cancer Research Virtual Annual Meeting

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced two upcoming virtual...

JNCE : 4.70 (-1.47%)
Jounce Therapeutics Reports First Quarter 2020 Financial Results

- Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 -

JNCE : 4.70 (-1.47%)
Jounce Therapeutics to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report...

JNCE : 4.70 (-1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade JNCE with:

Business Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator,...

See More

Key Turning Points

2nd Resistance Point 5.25
1st Resistance Point 5.01
Last Price 4.70
1st Support Level 4.62
2nd Support Level 4.47

See More

52-Week High 10.00
Fibonacci 61.8% 7.25
Fibonacci 50% 6.39
Fibonacci 38.2% 5.54
Last Price 4.70
52-Week Low 2.79

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar